Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared an article on X:
“SOFT/TEXT 15-year final results: tamoxifen remains reasonable for low-risk premenopausal HR+ disease; in young, HER2−, high-risk patients, OFS – and especially exemestane+OFS – provides a stronger endocrine backbone.”
Title: Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer
Authors: P.A. Francis, O. Pagani, G.F. Fleming, B.A. Walley, M. Colleoni, G. Rubovszky, C. Tondini, E.M. Ciruelos, H.L. Gomez, H.R. Bonnefoi, H.J. Burstein, C. Chini, F. Puglisi, S. Spazzapan, A. Bernardo, M.A. Climent, M. Bellet, T. Ruhstaller, B. Bermejo, S.K.L. Chia, S. Martino, C.E. Geyer Jr., M.P. Goetz, J.N. Ingle, V. Stearns, N.E. Davidson, F. Le Du, B. Müller, R.E. Coleman, S. Loibl, E.P. Winer, B. Ruepp, S. Loi, I. Láng, A.S. Coates, R.D. Gelber, A. Goldhirsch, M.M. Regan
Other articles featuring Yakup Ergün on OncoDaily.